ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcutis Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$31.89+3.07 (+10.65%)
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
90.2%
Operating margin
-3.3%
Net margin
-4.3%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +91.3% | +367.3% | – | – | |
| Gross profit | +91.3% | +387.3% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -132.0% | -9.3% | |
| Return on assets | – | -67.0% | -4.1% | |
| Current ratio | – | 12.96 | 3.17 | |
| Debt to equity | – | 0.00 | 0.58 | |
| Interest coverage | – | – | -1.0× | |
| Inventory turnover | – | – | 2.0× | |
| Capex to revenue | – | – | 0.2% | |
| Diluted shares | – | 36M | 127M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arcutis Biotherapeutics generated $797.18M from operations and spent $2.59M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$797.18M
Used
$2.59M
Capital expenditure$2.59M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-4.3%
×Asset turnover0.96×
×Equity multiplier2.25×
=Return on equity, FY2025-9.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -4.3% | 0.96× | 2.25× | -9.3% |
| FY2024 | -71.3% | 0.57× | 2.80× | -113.8% |
| FY2023 | -439.8% | 0.15× | 2.65× | -175.8% |
| FY2022 | -8449.8% | 0.01× | 1.69× | -122.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$16.14M
- Cash generatingOperating cash flow above zero-$5.63M
- Return on assets improvedROA up on the prior year-41.0% → -4.6%
- Earnings backed by cashOperating cash flow above net income-$5.63M vs -$16.14M
- Less leverageLong-term debt to assets fell30.7% → 24.9%
- Better liquidityCurrent ratio rose4.15 → 3.17
- No dilutionShare count did not rise121M → 127M
- Gross margin improvedGross margin up on the prior year90.27% → 90.24%
- More efficientAsset turnover rose0.58 → 1.08